The Chiba University mouse study (Translational Psychiatry, 2026) demonstrates that 14 days of clozapine dosing induces GI hypomotility, coordinated dysbiosis in both gut and lung compartments, and heightened mortality after LPS challenge. As an observational preclinical model with modest sample size and no randomization details reported, the work is hypothesis-generating rather than definitive; conflicts of interest are not disclosed. Building on earlier observational human data linking clozapine to severe constipation and pneumonia (e.g., a 2022 Australian cohort of 1,200 patients showing 3-fold elevated respiratory infection risk), the findings extend the gut-lung axis literature previously reviewed in Nature Reviews Microbiology (2023). Notably absent from the original coverage is discussion of sex-specific microbial shifts and potential adjunctive interventions such as short-chain fatty acid supplementation or motility-promoting probiotics, both of which have shown promise in separate rodent models of antipsychotic-induced dysbiosis. These results suggest that routine microbiome profiling or targeted prebiotics could be tested in future RCTs to reduce the drug’s life-threatening bowel and pulmonary complications.